WO2014152275A1 - Dérivés modifiés par le deutérium de l'inhibiteur de polymérase ns5b tcm647055 - Google Patents

Dérivés modifiés par le deutérium de l'inhibiteur de polymérase ns5b tcm647055 Download PDF

Info

Publication number
WO2014152275A1
WO2014152275A1 PCT/US2014/027151 US2014027151W WO2014152275A1 WO 2014152275 A1 WO2014152275 A1 WO 2014152275A1 US 2014027151 W US2014027151 W US 2014027151W WO 2014152275 A1 WO2014152275 A1 WO 2014152275A1
Authority
WO
WIPO (PCT)
Prior art keywords
deuterium
compound
hydrogen
another aspect
compounds
Prior art date
Application number
PCT/US2014/027151
Other languages
English (en)
Inventor
Adam Morgan
Original Assignee
Concert Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concert Pharmaceuticals, Inc. filed Critical Concert Pharmaceuticals, Inc.
Publication of WO2014152275A1 publication Critical patent/WO2014152275A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
    • C07D515/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • ADME absorption, distribution, metabolism and/or excretion
  • ADME limitation that affects many medicines is the formation of toxic or biologically reactive metabolites. As a result, some patients receiving the drug may experience toxicities, or the safe dosing of such drugs may be limited such that patients receive a suboptimal amount of the active agent. In certain cases,
  • vl modifying dosing intervals or formulation approaches can help to reduce clinical ad verse effects, but often the formation of such undesirable metabolites is intrinsic to the metabolism of the compound.
  • a metabolic inhibitor will be co-administered with a drug that is cleared too rapidly.
  • a drug that is cleared too rapidly.
  • the FDA recommends that these drugs be co-dosed with ritonavir, an inhibitor of cytochrome P450 enzyme 3A4
  • CYP3 A4 the enzyme typically responsible for their metabolism (see Kempf. D.J. et al, Antimicrobial agents and chemotherapy, 1997, 41(3): 654-60).
  • Ritonavir causes adverse effects and adds to the pill burden for HIV patients who must already take a combination of different drugs.
  • the CYP2D6 inhibitor quinidine has been added to dextromethorphan for the purpose of reducing rapid CYP2D6 metabolism of dextromethorphan in a treatment of pseudobulbar affect.
  • Quinidine however, has unwanted side effects that greatly limit its use in potential combination therapy (see Wang, L et al., Clinical Pharmacology and Therapeutics, 1994, 56(6 Pt 1): 659-67; and FDA label for quinidine at
  • a potentially attractive strategy for improving a drug's metabolic properties is deuterium modification.
  • Deuterium is a safe, stable, non-radioactive isotope of hydrogen. Compared to hydrogen, deuterium forms stronger bonds with carbon. In select cases, the increased bond strength imparted by deuterium can positively impact the ADME properties of a drug, creating the potential for improved drug efficacy, safety, and/or tolerability.
  • the size and shape of deuterium are essentially identical to those of hydrogen, replacement of hydrogen by deuterium would not be expected to affect
  • TMC-647055 also known as 13-cyclohexyl-3-meihoxy-17 ! 23-dimethyl-7I1- 10,6-(methanoiminothioiminoethanooxyethanoiminomethano)indolo[2, 1 - a][2]benzazepme-14,24-dione 16, 16-dioxide, a NS5B polymerase inhibitor, is currently being investigated in phase II clinical trials as a possible ali-oral combination therapy for the treatment of Hepatiti s C viral (HC V) infection.
  • the combination being investigated includes the NS5A inhibitor IDX719, the protease inhibitor simeprevir, as well as TMC-647055 boosted with low dose ritonavir.
  • This invention relates to NS5B polymerase inhibitors.
  • This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering NS5B polymerase inhibitors.
  • treat means decrease, suppress, attenuate, diminish, arrest or stabilize the development or progression of a disease (e.g., a disease or disorder delineated herein), lessen the severity of the disease or improve the symptoms associated with the disease.
  • Disease means any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
  • any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom.
  • a position is designated specifically as “H” or “hydrogen”
  • the position is understood to have hydrogen at its natural abundance isotopic composition.
  • a position is designated specifically as “D” or “deuterium”
  • the position is understood to have deuterium at an abundance that is at least 3000 times greater than the natural abundance of deuterium, which is 0.015% (i.e., at least 45% incorporation of deuterium).
  • isotopic enrichment factor means the ratio between the isotopic abundance and the natural abundance of a specified isotope.
  • a compound of this invention has an isotopic enrichment factor for each designated deuterium atom of at least 3500 (52.5% deuterium incorporation at each designated deuterium atom), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).
  • isotopologue refers to a species in which the chemical structure differs from a specific compound of this invention only in the isotopic composition thereof.
  • a compound represented by a particular chemical structure containing indicated deuterium atoms will also contain lesser amounts of isotopologues having hydrogen atoms at one or more of the desi gnated deuterium positions in that structure.
  • the relative amount of such isotopologues in a compound of this invention will depend upon a number of factors including the isotopic purity of deuterated reagents used to make the compound and the efficiency of incorporation of deuterium in the various synthesis steps used to prepare the compound.
  • the relative amount of such isotopologues in loto will be less than 55% of the compound. In other embodiments, the relative amount of such isotopologues in toto will be less than 50%o, less than 47.5%, less than 40%, less than 32.5%, less than 25%, less than 17.5%, less than 10%, less than 5%, less than 3%, less than 1%, or less than 0.5% of the compound.
  • the invention also provides salts of the compounds of the invention.
  • a salt of a compound of this invention is formed between an aci d and a basic group of the compound, such as an amino functional group, or a base and an acidic group of the compound, such as a carboxyl functional group.
  • the compound is a pharmaceutically acceptable acid addition salt.
  • a “pharmaceutically acceptable salt” means any non-toxic salt that, upon administration to a recipient, is capable of providing, either directly or indirectly, a compound of this invention.
  • a “pharmaceutically acceptable counterion” is an ionic portion of a salt that is not toxic when released from the salt upon administration to a recipient.
  • Acids commonly employed to form pharmaceutically acceptable salts include inorganic acids such as hydrogen bisulfide, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid and phosphoric acid, as well as organic acids such as para-toluenesulfonic acid, salicylic acid, tartaric acid, bitartaric acid, ascorbic acid, maleic acid, besylic acid, fumaric acid, gluconic acid, glucuronic acid, formic acid, glutamic acid, methanesulfonic acid, ethanesulfonic acid,
  • Such pharmaceutically acceptable salts thus include sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, phosphate,
  • pharmaceutically acceptable acid addition salts include those formed with mineral acids such as hydrochloric acid and hydrobromic acid, and especially those formed with organic acids such as maleic acid.
  • the pharmaceutically acceptable salt may also be a salt of a compound of the present invention and a base.
  • Exemplary bases include, but are not limited to.
  • morpholine thiomorpholine
  • piperidine pyrrolidine
  • amino acids such as arginine, lysine, and the like.
  • the compounds of the present invention may contain an asymmetric carbon atom, for example, as the result of deuterium substitution or otherwise.
  • compounds of this invention can exist as either individual enantiomers, or mixtures of the two enantiomers.
  • a compound of the present invention may exist as either a racemic mixture or a scalemic mixture, or as individual respective stereoisomers that are substantially free from another possible stereoisomer.
  • substantially free of other stereoisomers as used herein means less than 25% of other stereoisomers, preferably less than 10% of other stereoisomers, more preferably less than 5% of other stereoisomers and most preferably less than 2% of other stereoisomers are present.
  • stable compounds refers to compounds which possess stability sufficient to allow for their manufacture and which maintain the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., formulation into therapeutic products, intermediates for use in production of therapeutic compounds, isolatable or storable intermediate compounds, treating a disease or condition responsive to therapeutic agents).
  • a group is "substituted with” a substituent when one or more hydrogen atoms of the group are replaced with a corresponding number of substituent atoms (if the substituent is an atom) or groups (if the substituent is a group).
  • substituent refers to the replacement of one or more hydrogen atoms with a corresponding number of deuterium atoms.
  • variable may be referred to generally (e.g., "each Y”, “each R”, etc.) or may be referred to specifically (e.g., “Y Y 2 , Y 3 , ##, “R , R , ## etc.). Unless otherwise indicated, when a variable is referred to generally, it is meant to include all specific embodiments of that particular variable.
  • each Y is the same and is hydrogen or deuterium
  • each Y 2 is the same and is hydrogen or deuterium
  • each Y 3 is the same and is hydrogen or deuterium
  • each Y 4 is the same and is hydrogen or deuterium
  • each Y 5 is the same and is hydrogen or deuterium
  • 1596245.vl Y 6 is hydrogen or deuterium
  • each Y 7 is the same and is hydrogen or deuterium
  • each Y 8 is the same and is hydrogen or deuterium
  • each Y 9 is the same and is hydrogen or deuterium
  • R ⁇ and R 3 are each independently CH 3 or CD 3 ;
  • each Y is hydrogen, then at least one R is CD 3 .
  • each Y 1 and each Y 4 are hydrogen. In one aspect of this embodiment, each Y 2 and each Y 3 are hydrogen. In another aspect of this embodiment, each Y 2 and each Y 3 are deuterium. In one aspect of this embodiment, R and R 4 are each CH 3 . In another aspect of this embodiment, R and are each CD 3 . In one aspect R 1 is CD 3 and R 2 is CH 3 . In one aspect R l is CH 3 and R 2 is CD 3 . In one aspect of this embodiment, R 3 is CH 3 . In another aspect of this embodiment, R 3 is CD 3 . In one aspect of this embodiment, each Y 3 is hydrogen. In another aspect of this embodiment, each Y 5 is deuterium. In one aspect of this embodiment, Y 6 is hydrogen. In another aspect of this embodiment, Y 6 is deuterium. In one aspect of this embodim ent, each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium.
  • each Y 1 and each Y 4 are deuterium.
  • each Y 2 and each Y 3 are hydrogen.
  • each Y 2 and each Y 3 are deuterium.
  • R 1 and R 2 are each CH 3 .
  • R 1 and R 2 are each CD 3 .
  • R 1 is CH 3 and R 2 is CD 3 .
  • R 3 is CH 3 .
  • R 3 is CD 3 .
  • each Y 5 is hydrogen.
  • each Y 5 is deuterium.
  • Y 6 is hydrogen.
  • Y 6 is deuterium.
  • each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium.
  • each Y 2 and each Y 3 are hydrogen.
  • R 1 and R 2 are each CH .
  • R' and R " are each CD 3 .
  • R is CI I 3 .
  • R 3 is CD 3 .
  • each Y 5 is hydrogen.
  • each ⁇ ⁇ is deuterium.
  • Y 6 is hydrogen.
  • Y 6 is deuterium.
  • each Y 9 is hydrogen.
  • each Y 9 is deuterium.
  • each Y 2 and each Y 3 are deuterium.
  • R 1 and R 2 are each CH 3 .
  • R 1 and R 2 are each CD 3 .
  • R 3 is CH 3 .
  • R J is CD 3 .
  • each Y 0 is hydrogen.
  • each Y 5 is deuterium.
  • Y 6 is hydrogen.
  • Y 6 is deuterium.
  • each Y 9 is hydrogen.
  • each Y 9 is deuterium.
  • R ! and R 2 are each Ct3 ⁇ 4.
  • R 3 is CH 3 .
  • R 3 is CD 3 .
  • each Y 5 is hydrogen.
  • each Y 5 is deuterium.
  • Y 6 is hydrogen.
  • Y 6 is deuterium.
  • each Y 9 is hydrogen.
  • each Y 9 is deuterium.
  • R 1 and R 2 are each CD 3 .
  • R 3 is Cl3 ⁇ 4.
  • R J is CD 3 .
  • each Y 5 is hydrogen.
  • each Y 5 is deuterium.
  • Y 6 is hydrogen.
  • Y 6 is deuterium.
  • each Y 9 is hydrogen.
  • each Y 9 is deuterium.
  • R 3 is CH 3 .
  • each Y 5 is hydrogen. In another aspect of this embodiment, each Y 5 is deuterium. In one aspect of this embodiment.
  • Y 6 is hydrogen. In another aspect of this embodiment. Y 6 is deuterium.
  • each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium.
  • each Y J is hydrogen. In another aspect of this embodiment, each Y 5 is deuterium. In one aspect of this embodiment, Y 6 is hydrogen. In another aspect of this embodiment, Y 6 is deuterium. In one aspect of this embodiment, each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium.
  • each Y 5 is hydrogen. In one aspect of this embodiment, Y 6 is hydrogen. In another aspect of this embodiment, Y 6 is deuterium. In one aspect of this embodiment, each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium.
  • each Y 5 is deuterium.
  • Y 6 is hydrogen.
  • Y 6 is deuterium.
  • each Y 9 is hydrogen.
  • each Y 9 is deuterium.
  • Y 6 is hydrogen. In one aspect of this embodiment, each
  • each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium .
  • Y 6 is deuterium. In one aspect of this embodiment, each
  • each Y 9 is hydrogen. In another aspect of this embodiment, each Y 9 is deuterium.
  • each Y 9 is hydrogen. In another embodiment, each Y 9 is deuterium.
  • the compound of Formula I is any one of the compounds in Table 1 :
  • any atom not designated as deuterium in any of the embodiments set forth above is present at its natural isotopic abundance.
  • Such methods can be carried out utilizing corresponding deuterated and optionally, other isotope-containing reagents and/or intermediates to synthesize the compounds delineated herein, or invoking standard synthetic protocols known in the art for introducing isotopic atoms to a chemical structure.
  • Certain intennediates can be used with or without purification (e.g., filtration, distillation, sublimation, crystallization, trituration, solid phase extraction, and chromatography).
  • Bromo-indole 6 is converted to the corresponding boron pinacolate (7) which then undergoes Suzuki cross-coupling with aryl-bromide 8 to afford aldehyde 9.
  • Reaction of 9 with trimethyl-2- phosphonoacrylate (10) followed by ester hydrolysis provides intermediate 11 which is then coupled to diamine 12 affording 13.
  • Treatment of 13 with sulfuric diamide to give 14 hydrolysis of the t-butyl ester group to afford 15, and subsequent macrocyclization with carbon yl diimidazole ultimately provides compounds of Formula 1 with appropriate levels of deuteration based on the intermediates and reagent employed.
  • deuterated intermediate 2 may be obtained as outlined in
  • D2-cyclohexanone 2a may be prepared from ketone 16 and shown while analogs 2b, 2c, and 2d are all commercially available.
  • deuterated intermediate 8 may be obtained as outlined in Scheme 3 shown above.
  • Ds-arylbromide 8a can be prepared via alkylation of phenol 17 with Ds-iodomethane whereas compound 8b is commercially available from Sigma-Aldrich.
  • deuterated 10 may be prepared as outlined in Scheme 4 shown above according to the procedure described in OS patent application US
  • D 2 -phosphonoacrylate 10a can be prepared via reaction of 18 with D ⁇ -formaldehyde whereas compound 10b is prepared from formaldehyde.
  • Examples of deuterated 12 may be prepared as outlined in Scheme 5 shown above according to the procedure described in Krakowiak, K. et al. Acta Canale Pharmaceutica 1983, 40, 313-318.
  • D4-dicarboxylic acid 19a (commercially available from CDN Isotopes) may be converted to the bis acidchloride and subsequently converted to compounds 12a-12d via treatment with either methylamine or D3-methylamine (commercially available from Sigma-Aldrich).
  • compounds 12e-12h may be obtained i a similar fashion starting from dicarboxylic acid 19b.
  • the methods described in the foregoing may also additionally include steps, either before or after the steps described specifically herein, to add or remove suitable protecting groups in order to ultimately allow synthesis of the c ompounds herein.
  • various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
  • compositions comprising an effective amount of a compound of Formula 1 (e.g., including any of the formulae herein), or a pharmaceutically acceptable salt of said compound; and a
  • the carrier(s) are "acceptable” in the sense of being compatible with the other ingredients of the formulation and, in the case of a pharmaceutically acceptable carrier, not deleterious to the recipient thereof in an amount used in the medicament.
  • Pharmaceutically acceptable earners, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates. waxes, polyethylene-polyoxypropylene-b ock polymers, polyethylene glycol and wool fat.
  • solubility and bioavailability of the compounds of the present invention in pharmaceutical compositions may be enhanced by methods well-known in the art.
  • One method includes the use of lipid excipients in the formulation. See
  • Another known method of enhancing bioavailability is the use of an amorphous form of a compound of this invention optionally formulated with a poloxamer, such as LUTROLTM and PLURONICTM (BASF Corporation), or block copolymers of ethylene oxide and propylene oxide. See United States patent 7,014,866; and United States patent publications 20060094744 and 20060079502.
  • compositions of the invention include those suitable for oral, rectal, nasal, topical (including buccal and sublingual), vaginal or parenteral (including subcutaneous, intramuscular, intravenous and intradermal)
  • the compound of the formulae herein is administered transdermally (e.g., using a transdermal patch or iontophoretic techniques).
  • Other formulations may conveniently be presented in unit dosage form, e.g., tablets, sustained release capsules, and in liposomes, and may be prepared by any methods well known in the art of pharmacy. See, for example, Remington: The Science and Practice of Pharmacy, Lippincott Williams & Wilkins, Baltimore, MD (20th ed. 2000).
  • Such preparative methods include the step of bringing into association with the molecule to be administered ingredients such as the carrier that constitutes one or more accessory ingredients.
  • ingredients such as the carrier that constitutes one or more accessory ingredients.
  • the compositions are prepared by uniformly and intimately bringing into association the active ingredients with liquid carriers, liposomes or finely divided solid carriers, or both, and then, if necessary, shaping the product.
  • compositions of the present invention suitable for oral administration may be presented as discrete units such as capsules, sachets, or tablets each containing a predetermined amount of the active ingredient; a powder or granules; a solution or a suspension in an aqueous liquid or a non-aqueous liquid; an oil-in-water liquid emulsion; a water-in-oil liquid emulsion; packed in liposomes; or as a bolus, etc.
  • Soft gelatin capsules can be
  • carriers that are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried cornstarch.
  • compositions suitable for oral administration include lozenges comprising the ingredients in a flavored basis, usually sucrose and acacia or tragacanth; and pastilles comprising the active ingredient in an inert basis such as gelatin and glycerin, or sucrose and acacia.
  • compositions suitable for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions which may include suspending agents and thickening agents.
  • the formulations may be presented in unit-dose or multi-dose containers, for example, sealed ampules and vials, and may be stored in a freeze dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use.
  • Extemporaneous injection solutions and suspensions may be prepared from sterile powders, granules and tablets.
  • Such injection solutions may be in the form, for example, of a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example. Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3- butanedio).
  • the acceptable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic
  • 1S 6245 mono- or diglycerides.
  • Fatty acids such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically- acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • oils such as olive oil or castor oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant.
  • compositions of this invention may be administered in the form of suppositories for rectal administration.
  • These compositions can be prepared by mixing a compound of this invention with a suitable non -irritating excipient which is solid at room temperature but liquid at the rectal temperature and therefore wiil melt in the rectum to release the active components.
  • suitable non -irritating excipient include, but are not limited to, cocoa butter, beeswax and polyethylene glycols.
  • compositions of this invention may be administered b nasal aerosol or inhalation.
  • Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluoroearbons, and/or other solubilizing or dispersing agents known in the art. See, e.g.: Rabinowitz JD and Zaffaroni AC, US Patent 6,803,031, assigned to Alexza Molecular Delivery Corporation.
  • Topical administration of the pharmaceutical compositions of this invention is especially useful when the desired treatment involves areas or organs readily accessible by topical application.
  • the pharmaceutical composition should be formulated with a suitable ointment containing the active components suspended or dissolved in a carrier.
  • Carriers for topical administration of the compounds of this invention include, but are not limited to, mineral oil, liquid petroleum, white petroleum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax, and water.
  • the pharmaceutical composition can be formulated with a suitable lotion or cream containing the active compound suspended or dissolved in a carrier.
  • suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol. 2-octyldodecanol, benzyl alcohol, and water.
  • the pharmaceutical compositions of this invention may also be topically
  • Topically-transdermal patches and iontophoretic administration are also included in this invention.
  • Application of the subject therapeutics may be local, so as to be administered at the site of interest.
  • Various techniques can be used for providing the subject compositions at the site of interest, such as injection, use of catheters, trocars, projectiles, pluronic gel, stents, sustained drug release polymers or other device which provides for internal access.
  • the compounds of this invention may be incorporated into compositions for coating an implantable medical device, such as prostheses, artificial valves, vascular grafts, stents, or catheters.
  • an implantable medical device such as prostheses, artificial valves, vascular grafts, stents, or catheters.
  • Suitable coatings and the general preparation of coated implantable devices are known in the art and are exemplified in US Patents 6,099,562; 5,886,026; and 5,304, 121.
  • the coatings are typically biocompatible polymeric materials such as a hydrogel polymer, polymethyldisiloxane, polycaprolactone, polyethylene glycol, polylactic acid, ethylene vinyl acetate, and mixtures thereof.
  • the coatings may optionall be further covered by a suitable topcoat of fluorosilicone, polysaccharides, polyethylene glycol, phospholipids or combinations thereof to impart controlled release characteristics in the composition.
  • Coatings for invasive devices are to be included within the definition of pharmaceutically acceptable carrier, adjuvant or vehicle, as those terms are used herein.
  • the invention provides a method of coating an implantable medical device comprising the step of contacting said device with the coating composition described above. It will be obvious to those skilled in the art that the coating of the device will occur prior to implantation into a mammal.
  • the invention provides a method of impregnating an implantable drug release device comprising the step of contacting said drug release device with a compound or composition of thi s invention.
  • Implantable drug release devices include, but are not limited to, biodegradable polymer capsules or bullets, non-degradable, diffusible polymer capsules and biodegradable polymer wafers.
  • the invention provides an implantable medical device coated with a compound or a composition comprising a compound of this invention, such that said compound is therapeutically active.
  • the invention provides an implantable drug release device impregnated with or containing a compound or a composition comprising a compound of this invention, such that said compound is released from said device and is therapeutically active.
  • a composition of this invention may be painted onto the organ, or a composition of this invention may be applied in any other convenient way.
  • a composition of this invention further comprises a second therapeutic agent.
  • the second therapeutic agent may be selected from any compound or therapeutic agent known to have or that demonstrates advantageous properties when administered with a compound having the same mechanism of action as TMC-647055. Such agents include those indicated as being useful in combination with TMC-647055.
  • the second therapeutic agent is an agent useful in the treatment of HCV.
  • the second agent may be simeprevir, IDX71 , or a combination thereof.
  • the pharmaceutical composition may further comprise ritonavir, which may act as a boosting agent.
  • the invention provides separate dosage forms of a compound of this invention and one or more of any of the above -described second therapeutic agents, wherein the compound and second therapeutic agent are associated with one another.
  • association with one another means that the separate dosage fonns are packaged together or otherwise attached to one another such that it is readily apparent that the separate dosage forms are intended to be sold and administered together (within less than 24 hours of one another, consecutively or simultaneously).
  • the compound of the present invention is present in an effective amount.
  • the term is a pharmaceutically acceptable salt thereof.
  • an effective amount refers to an amount which, when administered in a proper dosing regimen, is sufficient to treat the target disorder.
  • an effective amount of a compound of this invention can range from about 10 mg to 5,000 mg per day, such as from about 100 to 3,000 mg per day, such as from about 150 to 2,000 mg per day, such as from about 200 mg to 1 ,000 mg per day.
  • Effective doses will also vary, as recognized by those skilled in the art, depending on the diseases treated, the severity of the disease, the route of administration, the sex, age and general health condition of the subject, excipient usage, the possibility of co-usage with other therapeutic treatments such as use of other agents and the judgment of the treating physician.
  • compositions that comprise a second therapeutic agent an effective amount of the second therapeutic agent is between about 20% and 100%) of the dosage normally utilized in a monotherapy regime using just that agent.
  • an effective amount is between about 70% and 100% of the normal monotherapeutic dose.
  • the normal monotherapeutic dosages of these second therapeutic agents are well known in the art. See. e.g., Wells et al.. eds.,
  • the invention provides a method of inhibiting S5B polymerase in a cell, comprising contacting a cell with a compound of Formula I herein.
  • the invention provides a method of treating a disease or condition that may be treated by TMC-647055, comprising
  • I596245 administering to a subject an effective amount of a compound or a composition of this invention.
  • the condition is HCV.
  • Identifying a subject in need of such treatment can be in the judgment of a subject or a health care professional and can be subjective (e.g. opinion) or objective
  • the subject is a patient.
  • any of the above methods of treatment comprises the further step of co-administering to the subject in need thereof one or more second therapeutic agents.
  • the choice of second therapeutic agent may be made from any second therapeutic agent known to be useful for co-administration with TMC- 647055, including but not limited to simeprevir, IDX719 and ritonavir.
  • the choice of second therapeutic agent is also dependent upon the particular disease or condition to be treated. Examples of second therapeutic agents that may be employed in the methods of this invention are therapeutics useful in treating myelofibrosis.
  • co-administered means that the second therapeutic agent may be administered together with a compound of this invention as part of a single dosage form (such as a composition of thi s invention comprising a compound of the invention and an second therapeutic agent as described above) or as separate, multiple dosage forms.
  • the additional agent may be administered prior to, consecutively with, or following the administration of a compound of this invention.
  • both the compounds of this invention and the second therapeutic agent(s) are administered by conventional methods.
  • composition of this invention comprising both a compound of the invention and a second therapeutic agent, to a subject does not preclude the separate administration of that same therapeutic agent, any other second therapeutic agent or any compound of thi s invention to said subject at another time during a course of treatment.
  • the effective amount of the compound of this invention is less than its effective amount would be where the second therapeutic agent is not administered. In another embodiment, the effective amount of the second therapeutic agent is less than its effective amount would be where the compound of this invention is not administered. In this way, undesired side effects associated with high doses of either agent may be minimized.
  • Other potential advantages including without limitation improved dosing regimens and/or reduced drug cost
  • the invention provides the use of a compound of Formula I alone or together with one or more of the above-described second therapeutic agents in the manufacture of a medicament, either as a single composition or as separate dosage forms, for treatment in a subject of a disease, disorder or symptom set forth above.
  • Another aspect of the invention is a compound of Formula I for use in the treatment in a subject of a disease, disorder or symptom thereof delineated herein.
  • Microsomal Assay The metabolic stability of compounds of Formula I is tested using pooled liver microsomal incubations. Full scan LC-MS analysis is then performed to detect major metabolites. Samples of the test compounds, exposed to pooled human liver microsomes, are analyzed using HPLC-MS (or MS/MS) detection. For determining metabolic stability, multiple reaction monitoring (MRM)
  • 1596245.vl is used to measure the disappearance of the test compounds.
  • Ql full scans are used as survey scans to detect the major metabolites.
  • Aliquots (200 iL) are withdrawn in triplicate at multiple time points (e.g., 0, 15, 30, 60, and 120 minutes) and combined with 800 ⁇ iL of ice-cold 50/50 acetonitrile/dH 2 0 to terminate the reaction.
  • the positive controls, testosterone and propranolol, as well as TMC-647055, are each run simultaneously with the test compounds in separate reactions.

Landscapes

  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne de nouveaux inhibiteurs de polymérase NS5B et des sels pharmaceutiquement acceptables de ceux-ci. Cette invention concerne également des compositions comprenant un composé de cette invention et l'utilisation de ces compositions dans des procédés de traitement de maladies et d'affections qui sont avantageusement traitées par l'administration d'inhibiteurs du VHC.
PCT/US2014/027151 2013-03-14 2014-03-14 Dérivés modifiés par le deutérium de l'inhibiteur de polymérase ns5b tcm647055 WO2014152275A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361785884P 2013-03-14 2013-03-14
US61/785,884 2013-03-14

Publications (1)

Publication Number Publication Date
WO2014152275A1 true WO2014152275A1 (fr) 2014-09-25

Family

ID=50478958

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2014/027151 WO2014152275A1 (fr) 2013-03-14 2014-03-14 Dérivés modifiés par le deutérium de l'inhibiteur de polymérase ns5b tcm647055

Country Status (1)

Country Link
WO (1) WO2014152275A1 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017202207A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé cyclique de naphtalène substitué, composition pharmaceutique et son application

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105473A1 (en) * 2008-07-08 2011-05-05 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110105473A1 (en) * 2008-07-08 2011-05-05 Tibotec Pharmaceuticals Macrocyclic indole derivatives useful as hepatitis c virus inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUMMINGS ET AL.: "Discovery and Early Development of TMC647055, a Non-Nucleoside Inhibitor of the Hepatitis C Virus NS5B Polymerase", J. MED. CHEM., vol. 57, no. 5, 21 October 2013 (2013-10-21), pages 1880 - 1892, XP055125826, ISSN: 0022-2623, DOI: 10.1021/jm401396p *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017202207A1 (fr) * 2016-05-27 2017-11-30 深圳市塔吉瑞生物医药有限公司 Composé cyclique de naphtalène substitué, composition pharmaceutique et son application

Similar Documents

Publication Publication Date Title
AU2013296627B2 (en) Deuterated ibrutinib
WO2012151361A1 (fr) Dérivés de carbamoylpyridone
AU2014205472B2 (en) Deuterated momelotinib
EP2872159A2 (fr) Carfilzomib deutéré
EP3492470A1 (fr) Palbociclib deutéré avec une stabilité métabolique améliorée
EP2935251A1 (fr) Inhibiteurs alk deutérés
WO2011017612A1 (fr) Dérivés de diphénylpyrazine substitués
US10385042B2 (en) Inhibitors of the enzyme UDP-glucose: N-acyl-sphingosine glucosyltransferase
US9107922B2 (en) Pyrimidinecarboxamide derivatives
WO2016061488A1 (fr) Inhibiteurs de réabsorption d'amines
WO2014152275A1 (fr) Dérivés modifiés par le deutérium de l'inhibiteur de polymérase ns5b tcm647055
EP2970213A1 (fr) Pacritinib deutérié
WO2015009889A1 (fr) Dérivés deutériés d'intédanib et leur utilisation pour le traitement de troubles prolifératifs
EP2885267B1 (fr) Idébénone deutérée
WO2010132663A1 (fr) Dérivés d'azapeptides pegylés utilisés en tant qu'inhibiteurs de la protéase du vih
WO2014150044A1 (fr) Inhibiteurs de réabsorption d'amines
US9181190B2 (en) Deuterated vercirnon
WO2011159920A1 (fr) Dérivés de [5,6]-dihydro-2h-pyran-2-one
WO2012027579A1 (fr) Dérivés de triterpénoïdes synthétiques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 14717026

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 14717026

Country of ref document: EP

Kind code of ref document: A1